| Identification | Back Directory | [Name]
Thalidomide-O-PEG4-Propargyl | [CAS]
2098799-77-8 | [Synonyms]
Thalidomide-PEG4-Propargyl
Thalidomide-O-PEG4-Propargyl
4-((3,6,9,12-tetraoxapentadec-14-yn-1-yl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione | [Molecular Formula]
C24H28N2O9 | [MDL Number]
MFCD32207014 | [MOL File]
2098799-77-8.mol | [Molecular Weight]
488.49 |
| Chemical Properties | Back Directory | [Boiling point ]
673.9±55.0 °C(Predicted) | [density ]
1.320±0.06 g/cm3(Predicted) | [solubility ]
Soluble in Water, DMF, DCM, DMSO | [form ]
Solid | [pka]
10.70±0.40(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Description]
Thalidomide-O-PEG4-Propargyl is synthesized compound that incorporates the Thalidomide based cereblon ligand and 4-unit PEG linker used in PROTAC technology, Propargyl is reactive with azide molecule in the presence of Cu catalyst. | [Uses]
Thalidomide-PEG4-Propargyl is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology[1]. Thalidomide-PEG4-Propargyl is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. | [IC 50]
Cereblon | [References]
[1] Sato T, et al. Cereblon-Based Small-Molecule Compounds to Control Neural Stem Cell Proliferation in Regenerative Medicine.?Front Cell Dev Biol. 2021;9:629326. Published 2021 Mar 11. DOI:10.3389/fcell.2021.629326
[2] Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-998. DOI:10.1016/j.str.2020.07.015 |
|
|